Pacira BioSciences, Inc. (NASDAQ:PCRX) Stock Holdings Increased by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund lifted its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 2.2% in the fourth quarter, Holdings Channel.com reports. The firm owned 26,964 shares of the company’s stock after acquiring an additional 591 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Pacira BioSciences were worth $910,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. abrdn plc lifted its position in shares of Pacira BioSciences by 14.3% in the fourth quarter. abrdn plc now owns 448,691 shares of the company’s stock worth $15,139,000 after purchasing an additional 56,081 shares in the last quarter. Gradient Investments LLC increased its holdings in Pacira BioSciences by 33.0% in the fourth quarter. Gradient Investments LLC now owns 139,949 shares of the company’s stock worth $4,722,000 after buying an additional 34,723 shares during the last quarter. Gotham Asset Management LLC increased its holdings in Pacira BioSciences by 16.8% in the third quarter. Gotham Asset Management LLC now owns 22,317 shares of the company’s stock worth $685,000 after buying an additional 3,203 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in Pacira BioSciences by 185.2% in the fourth quarter. Assenagon Asset Management S.A. now owns 246,621 shares of the company’s stock worth $8,321,000 after buying an additional 160,149 shares during the last quarter. Finally, Boston Partners increased its holdings in Pacira BioSciences by 105.4% in the third quarter. Boston Partners now owns 108,509 shares of the company’s stock worth $3,329,000 after buying an additional 55,679 shares during the last quarter. 99.73% of the stock is owned by hedge funds and other institutional investors.

Pacira BioSciences Stock Up 3.3 %

Shares of NASDAQ:PCRX opened at $26.33 on Monday. Pacira BioSciences, Inc. has a 52 week low of $25.33 and a 52 week high of $48.60. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.17 and a current ratio of 5.24. The company’s fifty day moving average is $28.71 and its 200-day moving average is $29.63. The company has a market capitalization of $1.22 billion, a PE ratio of 32.51 and a beta of 0.76.

Pacira BioSciences (NASDAQ:PCRX) last issued its earnings results on Thursday, February 29th. The company reported $0.71 EPS for the quarter, meeting the consensus estimate of $0.71. Pacira BioSciences had a net margin of 6.22% and a return on equity of 12.81%. The company had revenue of $181.24 million for the quarter, compared to the consensus estimate of $180.60 million. Equities research analysts predict that Pacira BioSciences, Inc. will post 2.18 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on PCRX shares. Wedbush restated an “outperform” rating and issued a $57.00 price objective on shares of Pacira BioSciences in a report on Thursday, February 8th. TheStreet raised shares of Pacira BioSciences from a “d+” rating to a “c” rating in a research report on Thursday, February 29th. HC Wainwright reaffirmed a “buy” rating and set a $57.00 target price on shares of Pacira BioSciences in a research report on Monday, March 4th. Royal Bank of Canada dropped their target price on shares of Pacira BioSciences from $53.00 to $45.00 and set an “outperform” rating on the stock in a research report on Friday, March 1st. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $45.00 target price on shares of Pacira BioSciences in a research report on Tuesday, April 9th. Eleven analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $49.50.

Insider Activity at Pacira BioSciences

In related news, Director Gary W. Pace sold 90,000 shares of Pacira BioSciences stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $30.60, for a total value of $2,754,000.00. Following the completion of the transaction, the director now directly owns 22,127 shares of the company’s stock, valued at $677,086.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Pacira BioSciences news, Director Gary W. Pace sold 90,000 shares of the business’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $30.60, for a total transaction of $2,754,000.00. Following the completion of the sale, the director now directly owns 22,127 shares of the company’s stock, valued at approximately $677,086.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gary W. Pace sold 1,066 shares of the business’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $29.67, for a total value of $31,628.22. Following the sale, the director now directly owns 140,384 shares of the company’s stock, valued at $4,165,193.28. The disclosure for this sale can be found here. 6.60% of the stock is currently owned by company insiders.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.